New Tendencies in the Development of the EU Competition Law – the AstraZeneca case
.
Saved in:
Main Author: | K. V. Entin |
---|---|
Format: | Article |
Language: | English |
Published: |
MGIMO University Press
2011-10-01
|
Series: | Vestnik MGIMO-Universiteta |
Online Access: | https://www.vestnik.mgimo.ru/jour/article/view/2106 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Busting the Breast Cancer with AstraZeneca’s Gefitinib
by: S. Chemmalar, et al.
Published: (2023-01-01) -
Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
by: Azhar Kareem Razzaq, et al.
Published: (2021-01-01) -
Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review
by: Paulo Diniz da Gama, et al.
Published: (2022-01-01) -
The new EU competition law
by: Alexander Burtscher
Published: (2024-04-01) -
Developments in the Case Law of the EU Courts in Competition Law in 2016
by: Catarina Vieira Peres
Published: (2017-04-01)